Cyber-Security Provider BIO-key Reports Q3 and Year-to-Date Revenues Rose to $1.4M and $5.3M, Respectively, on Growing Software and Services Revenue; Investor Call Tomorrow at 10am ET
BIO-key International, Inc. (Nasdaq: BKYI) reported a 6% revenue increase to $1.4M for Q3 2022 and a 26% year-to-date revenue rise to $5.3M, driven by software licenses and service fees. However, lower hardware sales impacted growth. The company expanded its global presence, securing customers in various sectors, while also launching the Mobile Authenticator App. Yet, they projected slower than expected sales, adjusting full-year revenue expectations to $7M-$9M. Operating expenses surged to $3.3M, leading to a net loss of $2.4M. Despite challenges, they remain optimistic about future growth and market opportunities.
- Q3 2022 revenues rose 6% to $1.4M and year-to-date revenues increased 26% to $5.3M.
- Expansion of global customer base in multiple sectors including healthcare and higher education.
- Launch of Mobile Authenticator App enhancing the company's IAM solutions.
- Acquisition of Swivel Secure Europe positions the company for significant growth in EMEA.
- Lower hardware revenue partially offsetting overall revenue growth.
- Net loss increased to $2.4M in Q3 2022, compared to $1.0M in Q3 2021.
- Total operating expenses increased to $3.3M due to higher SG&A and R&D costs.
WALL, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer identity and access management (IAM) and large-scale identity solutions, featuring Identity-Bound Biometrics (IBB), today reported results for its third quarter ended September 30, 2022 (Q3’22). BIO-key will host an investor call tomorrow at 10:00 a.m. ET (details below).
Q3 Highlights:
- Q3’22 revenues rose
6% to$1.4M vs. Q3’21 and year-to-date revenues increased26% to$5.3M , with increased software license and service fees which were partially offset by lower hardware revenue in both 2022 periods. - BIO-key expanded its global footprint with enterprise customers including a Dutch-based multi-national conglomerate and a leading Saudi Arabia healthcare procurement provider.
- Broadened partner network with Florida-based Darksteel Technologies and Israel’s Multi-Point Group.
- Advanced higher education franchise with PortalGuard deployments for the University of Arkansas at Fort Smith and California's Long Beach Community College District.
- Showcased Launch of our Mobile Authenticator App (MobileAuth), featuring both server-secured and on-device multi-biometrics at 2022 Gartner IAM Summit.
BIO-key Chairman & CEO Michael DePasquale commented, “Despite delays in our African business, some slippage from Q3 to Q4 in our domestic business, and seasonal slowness in Europe in the late summer, BIO-key continued to grow revenues and integrate our expanding operations. We have developed a substantial customer footprint generating high-margin annual recurring revenue (ARR) and our brand is now recognized on a global basis.
“Our integration of Swivel Secure Europe, which we acquired in March, is proceeding well, and we are now a truly global company. Through the first nine months of 2022, our sales by region grew in North America, Europe, the Middle East, South America, and Asia, but not in Africa, which continues to experience delays in the rollout of government sponsored national ID programs. In particular, the Nigerian Identity Management Commission has had both technical and financial issues that have led to delays in enrolling significant numbers of citizens, and we expect that to resolve itself in Q1 of 2023.
“Innovation remains core to our mission as we continue to expand password-less and mobile user IAM options, including the launch of BIO-key’s Mobile Authenticator App which supports both server-secured and on-device biometric multi-factor authentication (MFA). We also introduced an enhanced admin panel for our PortalGuard, Identity-as-a-Service (IDaaS) platform. Our PortalGuard IDaaS franchise continues to expand within higher education, county governments, and enterprises. Customers are drawn to this highly secure, efficient, user-friendly and cost-effective solution designed to meet today’s needs for scalable, secure on-site, mobile, and off-site user access.
“To enhance the global awareness and reach of our solutions and brand, we have invested in an expanded team of direct sales resources, supported by traditional and digital marketing.
“We believe the IAM and multi-factor authentication segments of the cybersecurity space are some of the most lucrative opportunities in the global software market right now. We are building a recurring annual revenue stream with a proven portfolio of Identity-as-a-Service products across customers in several key verticals. Our expanding global footprint of direct sales and distribution partner resources positions us well to address significant IAM and cybersecurity needs around the world. In addition to integrating Swivel Secure and launching BIO-key Europe, we’ve built a strong pipeline of significant customer and project opportunities, some of which have progressed more slowly than anticipated over the past several months, or slipped to Q4, as I had mentioned.
Outlook
“We expect a strong close to the year, however, given our slower than expected sales so far this year, we now expect full-year revenues of
“Our current outlook is supported by our technology leadership, our talented global sales, marketing and management teams, and the growing productivity of our channel partner program. With our acquisition of Swivel Secure Europe, we have added critical mass in Europe, the Middle East and Asia (EMEA). Accordingly, we expect to see significant EMEA growth moving into 2023 now that our team has been fully trained on the value and capabilities of our extended line of solutions and services.”
Financial Results
Q3’22 revenues rose
Gross profit was
Total operating expenses increased to
BIO-key reported a Q3’22 net loss of
Financial Strength
As of September 30, 2022, BIO-key had current assets of
Conference Call Details
| Date / Time: | Tuesday, November 15th at 10 a.m. ET |
| Call Dial In #: | 1-877-418-5460 U.S. or 1-412-717-9594 International |
| Live Webcast / Replay: | Investor Webcast & Replay – Available for 3 months. |
| Audio Replay: | 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 8070313 |
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key provides authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions, including PortalGuard that provides convenient and secure access to devices, information, applications, and high-value transactions. BIO-key's patented software and hardware solutions, with industry-leading biometric capabilities, enable large-scale on-premises and Identity-as-a-Service (IDaaS) solutions as well as customized enterprise and cloud solutions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology and identity access management industries; market acceptance of biometric products generally and our products under development; our ability to execute and deliver on contracts in Africa; our ability to expand into Asia, Africa, Europe, and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; the duration and severity of the current coronavirus COVID-19 pandemic and its effect on our business operations, sales cycles, personnel, and the geographic markets in which we operate; the duration and extent of continued hostilities in Ukraine and its impact on our European customers, delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
Engage with BIO-key
| Facebook – Corporate: | https://www.facebook.com/BIOkeyInternational/ |
| LinkedIn – Corporate: | https://www.linkedin.com/company/bio-key-international |
| Twitter – Corporate: | @BIOkeyIntl |
| Twitter – Investors: | @BIO_keyIR |
| StockTwits: | BIO_keyIR |
| Media Contact | Investor Contact |
| Erin Knapp | William Jones, David Collins |
| Matter Communications | Catalyst IR |
| BIO-key@matternow.com | BKYI@catalyst-ir.com |
| 914-260-3158 | 212-924-9800 |
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30, 2022 | December 31, 2021 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | 2,774,617 | $ | 7,754,046 | ||||
| Accounts receivable, net | 1,808,036 | 970,626 | ||||||
| Due from factor | 49,500 | 49,500 | ||||||
| Note receivable, net of allowance | - | 82,000 | ||||||
| Inventory | 4,892,667 | 4,940,660 | ||||||
| Prepaid expenses and other | 357,726 | 216,041 | ||||||
| Total current assets | 9,882,546 | 14,012,873 | ||||||
| Resalable software license rights | 41,286 | 48,752 | ||||||
| Investment – debt security, net | 262,821 | 452,821 | ||||||
| Equipment and leasehold improvements, net | 125,824 | 69,168 | ||||||
| Capitalized contract costs, net | 298,673 | 249,012 | ||||||
| Deposits and other assets | 8,712 | 8,712 | ||||||
| Note receivable, net of allowance | 146,000 | 113,000 | ||||||
| Operating lease right-of-use assets | 263,377 | 254,100 | ||||||
| Intangible assets, net | 1,799,074 | 1,298,077 | ||||||
| Goodwill | 2,197,698 | 1,262,526 | ||||||
| Total non-current assets | 5,143,465 | 3,756,168 | ||||||
| TOTAL ASSETS | $ | 15,026,011 | $ | 17,769,041 | ||||
| LIABILITIES | ||||||||
| Accounts payable | $ | 1,068,571 | $ | 427,772 | ||||
| Accrued liabilities | 875,903 | 828,997 | ||||||
| Earnout payable – Swivel acquisition | 500,000 | - | ||||||
| Government loan – BBVA Bank, current portion | 120,000 | - | ||||||
| Deferred revenue, current portion | 600,819 | 565,355 | ||||||
| Operating lease liabilities, current portion | 178,277 | 177,188 | ||||||
| Total current liabilities | 3,343,570 | 1,999,312 | ||||||
| Deferred revenue, net of current portion | 75,187 | 67,300 | ||||||
| Operating lease liabilities, net of current portion | 86,874 | 86,974 | ||||||
| Government loan – BBVA Bank, net of current portion | 321,872 | - | ||||||
| Total non-current liabilities | 483,933 | 154,274 | ||||||
| TOTAL LIABILITIES | 3,827,503 | 2,153,586 | ||||||
| Commitments and Contingencies | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Common stock — authorized, 170,000,000 shares; issued and outstanding; 8,452,621 and 7,853,759 of $.0001 par value at September 30, 2022 and December 31, 2021, respectively | 845 | 786 | ||||||
| Additional paid-in capital | 121,123,352 | 120,190,139 | ||||||
| Accumulated other comprehensive loss | (229,350 | ) | - | |||||
| Accumulated deficit | (109,696,339 | ) | (104,575,470 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 11,198,508 | 15,615,455 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 15,026,011 | $ | 17,769,041 | ||||
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
| Three months ended September 30, | Nine months ended September 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | ||||||||||||||||
| Services | $ | 371,956 | $ | 318,500 | $ | 1,202,866 | $ | 985,163 | ||||||||
| License fees | 918,260 | 870,459 | 3,540,592 | 2,011,610 | ||||||||||||
| Hardware | 83,333 | 109,870 | 518,377 | 1,182,784 | ||||||||||||
| Total revenues | 1,373,549 | 1,298,829 | 5,261,835 | 4,179,557 | ||||||||||||
| Costs and other expenses | ||||||||||||||||
| Cost of services | 162,632 | 176,976 | 554,222 | 511,360 | ||||||||||||
| Cost of license fees | 173,310 | 45,986 | 604,677 | 133,328 | ||||||||||||
| Cost of hardware | 57,841 | 71,712 | 296,278 | 656,190 | ||||||||||||
| Total costs and other expenses | 393,783 | 294,674 | 1,455,177 | 1,300,878 | ||||||||||||
| Gross profit | 979,766 | 1,004,155 | 3,806,658 | 2,878,679 | ||||||||||||
| Operating Expenses | ||||||||||||||||
| Selling, general and administrative | 2,510,706 | 1,385,534 | 6,315,277 | 4,276,016 | ||||||||||||
| Research, development and engineering | 829,506 | 612,597 | 2,418,855 | 1,545,200 | ||||||||||||
| Total Operating Expenses | 3,340,212 | 1,998,131 | 8,734,132 | 5,821,216 | ||||||||||||
| Operating loss | (2,360,446 | ) | (993,976 | ) | (4,927,474 | ) | (2,942,537 | ) | ||||||||
| Other income (expense) | ||||||||||||||||
| Interest income | 8 | 329 | 216 | 3,776 | ||||||||||||
| Loss on foreign currency transactions | - | - | - | (50,000 | ) | |||||||||||
| Investment-debt security reserve | (40,000 | ) | (30,000 | ) | (190,000 | ) | (30,000 | ) | ||||||||
| Noncash interest expense | - | - | - | (18,000 | ) | |||||||||||
| Interest expense | (2,071 | ) | - | (3,611 | ) | - | ||||||||||
| Total other income (expense), net | (42,063 | ) | (29,671 | ) | (193,395 | ) | (94,224 | ) | ||||||||
| Net loss | $ | (2,402,509 | ) | $ | (1,023,647 | ) | $ | (5,120,869 | ) | $ | (3,036,761 | ) | ||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (2,402,509 | ) | $ | (1,023,647 | ) | $ | (5,120,869 | ) | $ | (3,036,761 | ) | ||||
| Other comprehensive loss – Foreign currency translation adjustment | (119,269 | ) | - | (229,350 | ) | - | ||||||||||
| Net loss available to common stockholders | $ | (2,521,778 | ) | $ | (1,023,647 | ) | $ | (5,350,219 | ) | $ | (3,036,761 | ) | ||||
| Basic and Diluted Loss per Common Share | $ | (0.29 | ) | $ | (0.13 | ) | $ | (0.64 | ) | $ | (0.39 | ) | ||||
| Weighted Average Common Shares Outstanding: | ||||||||||||||||
| Basic and diluted | 8,148,848 | 7,790,778 | 8,054,207 | 7,788,734 | ||||||||||||
FAQ
What were BIO-key's Q3 2022 revenue results?
What is BKYI's updated revenue outlook for 2022?
What impact did hardware sales have on BIO-key's revenue?
How did operating expenses change for BIO-key in Q3 2022?
What is the significance of the Mobile Authenticator App launched by BIO-key?
